These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 34196700)

  • 1. Regional locus coeruleus degeneration is uncoupled from noradrenergic terminal loss in Parkinson's disease.
    Doppler CEJ; Kinnerup MB; Brune C; Farrher E; Betts M; Fedorova TD; Schaldemose JL; Knudsen K; Ismail R; Seger AD; Hansen AK; Stær K; Fink GR; Brooks DJ; Nahimi A; Borghammer P; Sommerauer M
    Brain; 2021 Oct; 144(9):2732-2744. PubMed ID: 34196700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the noradrenergic system in Parkinson's disease: an 11C-MeNER PET and neuromelanin MRI study.
    Sommerauer M; Fedorova TD; Hansen AK; Knudsen K; Otto M; Jeppesen J; Frederiksen Y; Blicher JU; Geday J; Nahimi A; Damholdt MF; Brooks DJ; Borghammer P
    Brain; 2018 Feb; 141(2):496-504. PubMed ID: 29272343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Noradrenergic alterations in Parkinson's disease: a combined 11C-yohimbine PET/neuromelanin MRI study.
    Laurencin C; Lancelot S; Brosse S; Mérida I; Redouté J; Greusard E; Lamberet L; Liotier V; Le Bars D; Costes N; Thobois S; Boulinguez P; Ballanger B
    Brain; 2024 Apr; 147(4):1377-1388. PubMed ID: 37787503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Locus coeruleus integrity and the effect of atomoxetine on response inhibition in Parkinson's disease.
    O'Callaghan C; Hezemans FH; Ye R; Rua C; Jones PS; Murley AG; Holland N; Regenthal R; Tsvetanov KA; Wolpe N; Barker RA; Williams-Gray CH; Robbins TW; Passamonti L; Rowe JB
    Brain; 2021 Sep; 144(8):2513-2526. PubMed ID: 33783470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In-vivo staging of pathology in REM sleep behaviour disorder: a multimodality imaging case-control study.
    Knudsen K; Fedorova TD; Hansen AK; Sommerauer M; Otto M; Svendsen KB; Nahimi A; Stokholm MG; Pavese N; Beier CP; Brooks DJ; Borghammer P
    Lancet Neurol; 2018 Jul; 17(7):618-628. PubMed ID: 29866443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brain-first versus body-first Parkinson's disease: a multimodal imaging case-control study.
    Horsager J; Andersen KB; Knudsen K; Skjærbæk C; Fedorova TD; Okkels N; Schaeffer E; Bonkat SK; Geday J; Otto M; Sommerauer M; Danielsen EH; Bech E; Kraft J; Munk OL; Hansen SD; Pavese N; Göder R; Brooks DJ; Berg D; Borghammer P
    Brain; 2020 Oct; 143(10):3077-3088. PubMed ID: 32830221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo detection of substantia nigra and locus coeruleus volume loss in Parkinson's disease using neuromelanin-sensitive MRI: Replication in two cohorts.
    Hwang KS; Langley J; Tripathi R; Hu XP; Huddleston DE
    PLoS One; 2023; 18(4):e0282684. PubMed ID: 37053195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mild cognitive impairment in de novo Parkinson's disease: A neuromelanin MRI study in locus coeruleus.
    Li Y; Wang C; Wang J; Zhou Y; Ye F; Zhang Y; Cheng X; Huang Z; Liu K; Fei G; Zhong C; Zeng M; Jin L
    Mov Disord; 2019 Jun; 34(6):884-892. PubMed ID: 30938892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Locus Coeruleus Shows a Spatial Pattern of Structural Disintegration in Parkinson's Disease.
    Madelung CF; Meder D; Fuglsang SA; Marques MM; Boer VO; Madsen KH; Petersen ET; Hejl AM; Løkkegaard A; Siebner HR
    Mov Disord; 2022 Mar; 37(3):479-489. PubMed ID: 35114035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuromelanin-sensitive magnetic resonance imaging features of the substantia nigra and locus coeruleus in de novo Parkinson's disease and its phenotypes.
    Wang J; Li Y; Huang Z; Wan W; Zhang Y; Wang C; Cheng X; Ye F; Liu K; Fei G; Zeng M; Jin L
    Eur J Neurol; 2018 Jul; 25(7):949-e73. PubMed ID: 29520900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased noradrenaline transporter density in the motor cortex of Parkinson's disease patients.
    Sommerauer M; Hansen AK; Parbo P; Fedorova TD; Knudsen K; Frederiksen Y; Nahimi A; Barbe MT; Brooks DJ; Borghammer P
    Mov Disord; 2018 Jul; 33(6):1006-1010. PubMed ID: 29797351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An investigation of neuromelanin distribution in substantia nigra and locus coeruleus in patients with Parkinson's disease using neuromelanin-sensitive MRI.
    Liu Q; Wang P; Liu C; Xue F; Wang Q; Chen Y; Hou R; Chen T
    BMC Neurol; 2023 Aug; 23(1):301. PubMed ID: 37580712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.
    Hansen AK; Knudsen K; Lillethorup TP; Landau AM; Parbo P; Fedorova T; Audrain H; Bender D; Østergaard K; Brooks DJ; Borghammer P
    Brain; 2016 Jul; 139(Pt 7):2039-49. PubMed ID: 27190023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preserved noradrenergic function in Parkinson's disease patients with rest tremor.
    Kinnerup MB; Sommerauer M; Damholdt MF; Schaldemose JL; Ismail R; Terkelsen AJ; Stær K; Hansen A; Fedorova TD; Knudsen K; Skjærbæk C; Borghammer P; Pavese N; Brooks DJ; Nahimi A
    Neurobiol Dis; 2021 May; 152():105295. PubMed ID: 33549722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo MRI assessment of the human locus coeruleus along its rostrocaudal extent in young and older adults.
    Betts MJ; Cardenas-Blanco A; Kanowski M; Jessen F; Düzel E
    Neuroimage; 2017 Dec; 163():150-159. PubMed ID: 28943414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microstructural integrity of the locus coeruleus and its tracts reflect noradrenergic degeneration in Alzheimer's disease and Parkinson's disease.
    Lin CP; Frigerio I; Bol JGJM; Bouwman MMA; Wesseling AJ; Dahl MJ; Rozemuller AJM; van der Werf YD; Pouwels PJW; van de Berg WDJ; Jonkman LE
    Transl Neurodegener; 2024 Feb; 13(1):9. PubMed ID: 38336865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PET imaging of noradrenaline transporters in Parkinson's disease: focus on scan time.
    Brumberg J; Tran-Gia J; Lapa C; Isaias IU; Samnick S
    Ann Nucl Med; 2019 Feb; 33(2):69-77. PubMed ID: 30293197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Noradrenergic Deficits in Parkinson Disease Imaged with
    Nahimi A; Sommerauer M; Kinnerup MB; Østergaard K; Winterdahl M; Jacobsen J; Schacht A; Johnsen B; Damholdt MF; Borghammer P; Gjedde A
    J Nucl Med; 2018 Apr; 59(4):659-664. PubMed ID: 28848039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Locus coeruleus imaging as a biomarker for noradrenergic dysfunction in neurodegenerative diseases.
    Betts MJ; Kirilina E; Otaduy MCG; Ivanov D; Acosta-Cabronero J; Callaghan MF; Lambert C; Cardenas-Blanco A; Pine K; Passamonti L; Loane C; Keuken MC; Trujillo P; Lüsebrink F; Mattern H; Liu KY; Priovoulos N; Fliessbach K; Dahl MJ; Maaß A; Madelung CF; Meder D; Ehrenberg AJ; Speck O; Weiskopf N; Dolan R; Inglis B; Tosun D; Morawski M; Zucca FA; Siebner HR; Mather M; Uludag K; Heinsen H; Poser BA; Howard R; Zecca L; Rowe JB; Grinberg LT; Jacobs HIL; Düzel E; Hämmerer D
    Brain; 2019 Sep; 142(9):2558-2571. PubMed ID: 31327002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Noradrenergic pathways of locus coeruleus in Parkinson's and Alzheimer's pathology.
    Singh S
    Int J Neurosci; 2020 Mar; 130(3):251-261. PubMed ID: 31575316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.